Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer.
Oka T, Hatano K, Okuda Y, Yamamoto A, Uemura T, Yamamichi G, Tomiyama E, Ishizuya Y, Yamamoto Y, Kato T, Kawashima A, Fujita K, Nonomura N. Oka T, et al. Among authors: okuda y. Int J Clin Oncol. 2023 Mar;28(3):427-435. doi: 10.1007/s10147-022-02288-5. Epub 2022 Dec 29. Int J Clin Oncol. 2023. PMID: 36580184
Bacteria-derived DNA in serum extracellular vesicles are biomarkers for renal cell carcinoma.
Uemura T, Kawashima A, Jingushi K, Motooka D, Saito T, Nesrine S, Oka T, Okuda Y, Yamamoto A, Yamamichi G, Tomiyama E, Ishizuya Y, Yamamoto Y, Kato T, Hatano K, Tsujikawa K, Wada H, Nonomura N. Uemura T, et al. Among authors: okuda y. Heliyon. 2023 Sep 6;9(9):e19800. doi: 10.1016/j.heliyon.2023.e19800. eCollection 2023 Sep. Heliyon. 2023. PMID: 37810127 Free PMC article.
Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan.
Yoshimura A, Kato T, Nakai Y, Tsujihata M, Toyoda S, Sato M, Matsuzaki K, Nakata W, Takao T, Inoguchi S, Okuda Y, Yamamichi G, Ishizuya Y, Yamamoto Y, Hatano K, Kawashima A, Takada S, Inoue H, Nishimura K, Miyake O, Fujita K, Nakayama M, Nishimura K, Nonomura N. Yoshimura A, et al. Among authors: okuda y. Int J Clin Oncol. 2024 Dec;29(12):1916-1924. doi: 10.1007/s10147-024-02612-1. Epub 2024 Sep 2. Int J Clin Oncol. 2024. PMID: 39222148 Free PMC article.
Serum D-asparagine concentration adjusted for eGFR could serve as a novel screening tool for urothelial carcinoma.
Yamamoto A, Kawashima A, Sakai S, Mita M, Sassi N, Inoguchi S, Horibe Y, Yoshimura A, Tani M, Yutong L, Okuda Y, Oka T, Uemura T, Yamamichi G, Ishizuya Y, Hayashi T, Yamamoto Y, Kato T, Hatano K, Kakuta Y, Imamura R, Takahara S, Kimura T, Nonomura N. Yamamoto A, et al. Among authors: okuda y. Biochem Biophys Res Commun. 2024 Nov 12;733:150701. doi: 10.1016/j.bbrc.2024.150701. Epub 2024 Sep 14. Biochem Biophys Res Commun. 2024. PMID: 39326256 Free article.
PSA Kinetics Affect Prognosis in Patients With Castration-resistant Prostate Cancer Treated With Enzalutamide.
Oka T, Hatano K, Tani M, Yoshimura A, Horibe Y, Liu Y, Sassi N, Okuda Y, Yamamoto A, Uemura T, Yamamichi G, Ishizuya YU, Yamamoto Y, Kato T, Kawashima A, Fujita K, Nonomura N. Oka T, et al. Among authors: okuda y. Cancer Diagn Progn. 2024 Nov 3;4(6):706-714. doi: 10.21873/cdp.10385. eCollection 2024 Nov-Dec. Cancer Diagn Progn. 2024. PMID: 39502601 Free PMC article.
1,182 results